DK2109623T3 - Cancerbehandling med anti-IL-1-antistoffer - Google Patents

Cancerbehandling med anti-IL-1-antistoffer

Info

Publication number: DK2109623T3
Authority: DK; Denmark
Prior art keywords: cancer treatment; antibodies; immunization; antibody; patient
Prior art date: 2006-05-22

Application number

DK07734628.6T

Other languages

English (en)

Inventor

John Simard

Original Assignee

Xbiotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-22

Filing date

2007-05-22

Publication date

2012-01-30

2007-05-22 Application filed by Xbiotech Inc filed Critical Xbiotech Inc

2012-01-30 Application granted granted Critical

2012-01-30 Publication of DK2109623T3 publication Critical patent/DK2109623T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK07734628.6T 2006-05-22 2007-05-22 Cancerbehandling med anti-IL-1-antistoffer DK2109623T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80216606P	2006-05-22	2006-05-22
PCT/IB2007/001320 WO2007135546A2 (en)	2006-05-22	2007-05-22	TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES

Publications (1)

Publication Number	Publication Date
DK2109623T3 true DK2109623T3 (da)	2012-01-30

Family

ID=38670649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07734628.6T DK2109623T3 (da)	2006-05-22	2007-05-22	Cancerbehandling med anti-IL-1-antistoffer

Country Status (15)

Country	Link
US (3)	US20100040574A1 (da)
EP (1)	EP2109623B1 (da)
JP (3)	JP2009537628A (da)
CN (3)	CN102580086A (da)
AT (1)	ATE528319T1 (da)
AU (1)	AU2007252990B2 (da)
CA (1)	CA2652870C (da)
CY (1)	CY1112288T1 (da)
DK (1)	DK2109623T3 (da)
ES (1)	ES2374845T3 (da)
HK (1)	HK1243943A1 (da)
PL (1)	PL2109623T3 (da)
PT (1)	PT2109623E (da)
SI (1)	SI2109623T1 (da)
WO (1)	WO2007135546A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE470151T1 (de) *	2005-08-02	2010-06-15	Xbiotech Inc	Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
US20110008282A1 (en) *	2006-05-15	2011-01-13	Xbiotech, Inc.	IL-1alpha immunization induces autoantibodies protective against atherosclerosis
JP5670318B2 (ja) *	2008-05-30	2015-02-18	エックスバイオテク, インコーポレイテッドXbiotech, Inc.	インターロイキン１α抗体及び有用な方法
CN102209557A (zh) *	2008-09-12	2011-10-05	埃克斯生物科技公司	靶向病原性单核细胞
BR122014011544A2 (pt)	2010-05-14	2019-08-13	Abbvie Inc	proteínas de ligação à il-1
EP2582391B1 (en)	2010-06-18	2018-10-03	XBiotech, Inc	Arthritis treatment
AU2015201228B2 (en) *	2010-08-23	2016-02-11	Xbiotech Inc.	Treatment for neoplastic diseases
AU2015271978B2 (en) *	2010-08-23	2017-10-26	Xbiotech Inc.	Treatment for neoplastic diseases
KR20210128021A (ko) *	2010-08-23	2021-10-25	얀센 바이오테크 인코포레이티드	종양성 질병들에 대한 치료
US9724409B2 (en) *	2011-04-01	2017-08-08	Xbiotech, Inc.	Treatment of inflammatory skin disease
PT2750709T (pt) *	2011-09-23	2018-11-22	Xbiotech Inc	Tratamento da caquexia
US9545441B2 (en)	2012-09-18	2017-01-17	Xbiotech, Inc.	Treatment of diabetes
AU2018220862A1 (en)	2017-02-16	2019-08-29	Janssen Biotech, Inc.	Treatment of hidradenitis suppurativa
US10975146B2 (en)	2018-06-29	2021-04-13	Cedars-Sinai Medical Center	Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095676A1 (en) *	2020-10-07	2022-04-07	Xbiotech Inc.	True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH652145A5 (de) *	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) *	1984-07-05	1997-09-30	Genentech, Inc.	Tumor necrosis factor antagonists and their use
US5168062A (en) *	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) *	1985-12-24	1990-10-23	Konica Corporation	Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) *	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPH06339394A (ja) *	1986-11-13	1994-12-13	Otsuka Pharmaceut Co Ltd	ヒトインターロイキン−１αに対するモノクローナル抗体
US5034316A (en) *	1987-03-30	1991-07-23	The Regents Of The University Of California	In vitro human monoclonal IgG rheumatoid factor autoantibody
JPH02157231A (ja) *	1988-12-07	1990-06-18	Bio Kagaku Kenkyusho:Kk	細胞増殖抑制剤
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
JPH08502300A (ja) *	1992-10-14	1996-03-12	スターリングウィンスロップアイエヌシー．	治療および診断像形成組成物および方法
ATE204299T1 (de) *	1993-03-05	2001-09-15	Bayer Ag	Humane monoklonale anti-tnf alpha antikörper
US5959085A (en) *	1993-11-23	1999-09-28	Schering Corporation	Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
WO1997002479A2 (en) *	1995-06-30	1997-01-23	Yale University	Human monoclonal anti-tumor antibodies
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
SE9802402D0 (sv) *	1998-07-03	1998-07-03	Karolinska Innovations Ab	Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) *	1999-03-12	2003-02-27	Rosen Craig A.	Nucleic acids, proteins and antibodies
US20030232054A1 (en) *	2000-01-25	2003-12-18	Tang Y. Tom	Novel nucleic acids and polypeptides
US6623736B2 (en) *	2000-05-02	2003-09-23	Edward L. Tobinick	Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) *	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
EA033750B1 (ru) *	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
HN2004000285A (es) *	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) *	2003-12-24	2010-09-21	Henry John Smith	Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) *	2004-02-03	2006-09-12	The Regents Of The University Of California	Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) *	2004-05-25	2006-01-05	Sloan-Kettering Institute For Cancer Research	Migrastatin analogs in the treatment of cancer
ATE470151T1 (de) *	2005-08-02	2010-06-15	Xbiotech Inc	Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
ATE551365T1 (de) *	2006-05-15	2012-04-15	Xbiotech Inc	Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.
US20110008282A1 (en) *	2006-05-15	2011-01-13	Xbiotech, Inc.	IL-1alpha immunization induces autoantibodies protective against atherosclerosis
JP2009538629A (ja) *	2006-05-30	2009-11-12	ジェネンテック・インコーポレーテッド	抗体およびイムノコンジュゲートとこれらの使用方法
JP5670318B2 (ja) *	2008-05-30	2015-02-18	エックスバイオテク, インコーポレイテッドXbiotech, Inc.	インターロイキン１α抗体及び有用な方法
CN102209557A (zh) *	2008-09-12	2011-10-05	埃克斯生物科技公司	靶向病原性单核细胞

2007
- 2007-05-22 CN CN2012100439005A patent/CN102580086A/zh active Pending
- 2007-05-22 ES ES07734628T patent/ES2374845T3/es active Active
- 2007-05-22 WO PCT/IB2007/001320 patent/WO2007135546A2/en active Application Filing
- 2007-05-22 SI SI200730797T patent/SI2109623T1/sl unknown
- 2007-05-22 AT AT07734628T patent/ATE528319T1/de active
- 2007-05-22 EP EP07734628A patent/EP2109623B1/en active Active
- 2007-05-22 PT PT07734628T patent/PT2109623E/pt unknown
- 2007-05-22 US US12/302,066 patent/US20100040574A1/en not_active Abandoned
- 2007-05-22 PL PL07734628T patent/PL2109623T3/pl unknown
- 2007-05-22 JP JP2009511597A patent/JP2009537628A/ja not_active Withdrawn
- 2007-05-22 DK DK07734628.6T patent/DK2109623T3/da active
- 2007-05-22 AU AU2007252990A patent/AU2007252990B2/en active Active
- 2007-05-22 CN CNA2007800231112A patent/CN101472948A/zh active Pending
- 2007-05-22 CN CN201710383172.5A patent/CN107158376A/zh active Pending
- 2007-05-22 CA CA2652870A patent/CA2652870C/en active Active
2012
- 2012-01-05 CY CY20121100014T patent/CY1112288T1/el unknown
2013
- 2013-01-25 JP JP2013011701A patent/JP5992843B2/ja active Active
2015
- 2015-07-03 JP JP2015134049A patent/JP6359492B2/ja active Active
2016
- 2016-02-02 US US15/013,469 patent/US20160159899A1/en not_active Abandoned
2018
- 2018-03-13 HK HK18103522.1A patent/HK1243943A1/zh unknown
2019
- 2019-02-08 US US16/271,235 patent/US20190169287A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1112288T1 (el)	2015-12-09
CN107158376A (zh)	2017-09-15
CN102580086A (zh)	2012-07-18
PL2109623T3 (pl)	2012-03-30
JP5992843B2 (ja)	2016-09-14
CA2652870C (en)	2014-12-02
EP2109623A2 (en)	2009-10-21
PT2109623E (pt)	2012-01-12
EP2109623B1 (en)	2011-10-12
ES2374845T3 (es)	2012-02-22
JP2009537628A (ja)	2009-10-29
CA2652870A1 (en)	2007-11-29
JP2015166401A (ja)	2015-09-24
US20190169287A1 (en)	2019-06-06
CN101472948A (zh)	2009-07-01
US20160159899A1 (en)	2016-06-09
JP6359492B2 (ja)	2018-07-18
WO2007135546A2 (en)	2007-11-29
US20100040574A1 (en)	2010-02-18
AU2007252990B2 (en)	2011-10-27
SI2109623T1 (sl)	2012-05-31
HK1243943A1 (zh)	2018-07-27
AU2007252990A1 (en)	2007-11-29
JP2013126990A (ja)	2013-06-27
WO2007135546A3 (en)	2008-02-07
ATE528319T1 (de)	2011-10-15

Publication	Publication Date	Title
DK2109623T3 (da)	2012-01-30	Cancerbehandling med anti-IL-1-antistoffer
CY1124144T1 (el)	2022-05-27	Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1115871T1 (el)	2017-01-25	Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
NL301089I2 (nl)	2021-02-04	imlifidase
HUE048404T2 (hu)	2020-07-28	Claudin-18 elleni monoklonális antitestek rák kezelésére
EA200900040A1 (ru)	2009-06-30	Молекулы антител, которые связываются с человеческим il-17
AR059922A1 (es)	2008-05-07	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
DK3401334T5 (da)	2024-09-23	Monoklonale antistoffer mod claudin-18 til cancerbehandling
CY1110783T1 (el)	2015-06-10	Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
NO20083891L (no)	2008-12-03	Anti-5T4 antistoffer og anvendelser derav
IL197217B (en)	2019-12-31	Novel anti-cd38 antibodies for the treatment of cancer
CA3019531A1 (en)	2012-10-26	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EA201100923A1 (ru)	2011-12-30	Антитела человека против тканевого фактора
NO20084546L (no)	2008-12-23	Diagnostikk og behandlinger for tumorer
NZ592215A (en)	2012-09-28	c-MET ANTIBODIES
EA201000644A1 (ru)	2011-04-29	Антитела для лечения и профилактики болезни альцгеймера и их применение
CL2007002404A1 (es)	2008-04-18	Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
EA201171060A1 (ru)	2012-07-30	Молекулы антител, обладающих специфичностью к человеческому ох40
CY1113640T1 (el)	2016-06-22	Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY2022028I1 (el)	2023-01-05	Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
DK1869185T3 (da)	2010-06-21	Konjugat med P21-protein til kræftbehandling
AR055072A1 (es)	2007-08-01	Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
WO2007007160A3 (en)	2007-05-18	Anti-madcam antibodies to treat fever
UA108207C2 (xx)	2015-04-10	Високоафінне людське антитіло до людського ангіопоетину-2
UA97645C2 (ru)	2012-03-12	АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ РЕЦЕПТОР ИНТЕРЛЕЙКИНА-6 ЧЕЛОВЕКА (hIL-6R)